Abstract
Background South Africa faces emerging resistance to key TB drugs, including bedaquiline. Phenotypic drug susceptibility testing (pDST), the current reference standard for bedaquiline DST, while accurate has long turnaround times. Targeted next-generation sequencing (tNGS) offers a comprehensive alternative to pDST, potentially delivering faster results. However, its advantages must be weighed against differences in implementation cost and test accuracy. Methods We used a decision tree model to evaluate the cost-effectiveness of tNGS against the standard of care (SOC) in South Africa at different levels of tNGS decentralization (1, 3, 4, or 6 sites). Key outcomes considered were survival rates, time to a correct resistance profile, duration of infectiousness, and disability-adjusted life years (DALYs). Sensitivity analyses assessed the impact of drug resistance prevalence, tNGS sensitivity, and improved DST access on DALYs and incremental cost per DALY averted. Results tNGS averted 408 DALYs and returned a greater number of correct resistance profiles (90.7%) as compared to the SOC (87.7%). Based on model and scenario assumptions for South Africa, tNGS returned results with a reduced turnaround time and averted 96 years of infectious time. Centralized tNGS was determined to be cost-saving relative to the SOC, however decentralization of tNGS resulted in higher incremental costs per DALY averted ($671- $2,454). tNGS performance relative to the SOC improved at higher bedaquiline resistance prevalence and when tNGS sensitivity increased. Access gains through tNGS increased the number of DALYs averted and decreased the respective incremental cost per DALY averted for decentralized scenarios. Conclusions Centralized tNGS testing is likely to be cost-saving in South Africa and decentralised tNGS would result in higher costs but could be cost-effective under current assumptions. Additionally, tNGS has the potential to reduce DALYs, shorten result turnaround times, and decrease infectious duration while improving the percentage of individuals receiving correct DST results.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Support for this project was provided through funding from Unitaid (2019-32-FIND MDR). The funder of this study had no role in study design, data collection and analysis, data interpretation, decision to publish, or preparation of the manuscript. The view expressed by the authors do not necessarily reflect the views of the funding agency.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos